Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1998 Jun;57(6):346–349. doi: 10.1136/ard.57.6.346

Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women

T Masud 1, B Mulcahy 1, A Thompson 1, S Donnelly 1, R Keen 1, D Doyle 1, T Spector 1
PMCID: PMC1752624  PMID: 9771208

Abstract

OBJECTIVES—Few data are available on the effects of combination therapy for the treatment of osteoporosis. The aim of this study was to compare the effects of intermittent cyclical etidronate (E) therapy alone with a combination of cyclical etidronate and calcitriol (E+C) on spine and femoral neck bone mineral density (BMD) at one year.
METHODS—Postmenopausal women with at least one non-traumatic vertebral fracture or z score < −1.5 were randomly allocated to an E group (each cycle = oral etidronate 400 mg daily for 14 days followed by calcium 500 mg daily for 76 days) or an E+C group (as for E plus oral calcitriol 0.5 µg daily). Lumbar spine and femoral neck BMDs were measured by dual energy x ray absorptiometry at baseline and at one year. The study design did not contain a placebo group.
RESULTS—The mean % increase in lumbar spine BMD was 5.2% (95%CI= 3.4 to 7.0) in the E+C group (n=24), which was significantly greater than the 2.7% (95%CI= 1.3 to 4.1) increase in the E group (n=23) (p<0.05). The femoral neck BMD in the E+C group increased by 2.0% (95%CI= 0.8 to 3.2), which was significantly different from the E group where there was a −0.4% (95%CI=−2.4 to 1.6) change (p=0.046).
CONCLUSIONS—These data show that a combination of cyclical etidronate and calcitriol is better than cyclical etidronate alone in terms of changes in BMD at both spine and femoral neck sites. Although further data are needed on fracture efficacy, this study suggests that combination therapies have additive therapeutic potential that may exceed that expected from their theoretical mode of action.

 Keywords: bone density; calcitriol; etidronate; osteoporosis

Full Text

The Full Text of this article is available as a PDF (98.7 KB).

Figure 1  .

Figure 1  

Open in a new tab

Percentage change in lumbar spine and femoral neck BMD at one year for the intermittent cyclical etidronate (E) and combined intermittent cyclical etidronate and calcitriol (E+C) therapies.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aloia J. F., Vaswani A., Yeh J. K., Ellis K., Yasumura S., Cohn S. H. Calcitriol in the treatment of postmenopausal osteoporosis. Am J Med. 1988 Mar;84(3 Pt 1):401–408. doi: 10.1016/0002-9343(88)90259-8. [DOI] [PubMed] [Google Scholar]
  2. Chapuy M. C., Arlot M. E., Duboeuf F., Brun J., Crouzet B., Arnaud S., Delmas P. D., Meunier P. J. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med. 1992 Dec 3;327(23):1637–1642. doi: 10.1056/NEJM199212033272305. [DOI] [PubMed] [Google Scholar]
  3. Evans R. A., Somers N. M., Dunstan C. R., Royle H., Kos S. The effect of low-dose cyclical etidronate and calcium on bone mass in early postmenopausal women. Osteoporos Int. 1993 Mar;3(2):71–75. doi: 10.1007/BF01623376. [DOI] [PubMed] [Google Scholar]
  4. Francis R. M., Peacock M. Local action of oral 1,25-dihydroxycholecalciferol on calcium absorption in osteoporosis. Am J Clin Nutr. 1987 Aug;46(2):315–318. doi: 10.1093/ajcn/46.2.315. [DOI] [PubMed] [Google Scholar]
  5. Gallagher J. C., Goldgar D. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med. 1990 Nov 1;113(9):649–655. doi: 10.7326/0003-4819-113-9-649. [DOI] [PubMed] [Google Scholar]
  6. Harris S. T., Watts N. B., Jackson R. D., Genant H. K., Wasnich R. D., Ross P., Miller P. D., Licata A. A., Chesnut C. H., 3rd Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med. 1993 Dec;95(6):557–567. doi: 10.1016/0002-9343(93)90350-x. [DOI] [PubMed] [Google Scholar]
  7. Lips P., Graafmans W. C., Ooms M. E., Bezemer P. D., Bouter L. M. Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med. 1996 Feb 15;124(4):400–406. doi: 10.7326/0003-4819-124-4-199602150-00003. [DOI] [PubMed] [Google Scholar]
  8. Miller P. D., Neal B. J., McIntyre D. O., Yanover M. J., Anger M. S., Kowalski L. Effect of cyclical therapy with phosphorus and etidronate on axial bone mineral density in postmenopausal osteoporotic women. Osteoporos Int. 1991 Jun;1(3):171–176. doi: 10.1007/BF01625449. [DOI] [PubMed] [Google Scholar]
  9. Morrison N. A., Qi J. C., Tokita A., Kelly P. J., Crofts L., Nguyen T. V., Sambrook P. N., Eisman J. A. Prediction of bone density from vitamin D receptor alleles. Nature. 1994 Jan 20;367(6460):284–287. doi: 10.1038/367284a0. [DOI] [PubMed] [Google Scholar]
  10. Ooms M. E., Roos J. C., Bezemer P. D., van der Vijgh W. J., Bouter L. M., Lips P. Prevention of bone loss by vitamin D supplementation in elderly women: a randomized double-blind trial. J Clin Endocrinol Metab. 1995 Apr;80(4):1052–1058. doi: 10.1210/jcem.80.4.7714065. [DOI] [PubMed] [Google Scholar]
  11. Orimo H., Shiraki M., Hayashi T., Nakamura T. Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1 alpha (OH)-vitamin D3. Bone Miner. 1987 Oct;3(1):47–52. [PubMed] [Google Scholar]
  12. Orimo H., Shiraki M., Hayashi Y., Hoshino T., Onaya T., Miyazaki S., Kurosawa H., Nakamura T., Ogawa N. Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int. 1994 May;54(5):370–376. doi: 10.1007/BF00305521. [DOI] [PubMed] [Google Scholar]
  13. Ott S. M., Chesnut C. H., 3rd Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med. 1989 Feb 15;110(4):267–274. doi: 10.7326/0003-4819-110-4-267. [DOI] [PubMed] [Google Scholar]
  14. Ranstam J., Kanis J. A. Influence of age and body mass on the effects of vitamin D on hip fracture risk. Osteoporos Int. 1995;5(6):450–454. doi: 10.1007/BF01626607. [DOI] [PubMed] [Google Scholar]
  15. Reynolds J. J., Holick M. F., De Luca H. F. The role of vitamin D metabolites in bone resorption. Calcif Tissue Res. 1973;12(4):295–301. doi: 10.1007/BF02013742. [DOI] [PubMed] [Google Scholar]
  16. Silberstein E. B., Schnur W. Cyclic oral phosphate and etidronate increase femoral and lumbar bone mineral density and reduce lumbar spine fracture rate over three years. J Nucl Med. 1992 Jan;33(1):1–5. [PubMed] [Google Scholar]
  17. Spector T. D., Keen R. W., Arden N. K., Morrison N. A., Major P. J., Nguyen T. V., Kelly P. J., Baker J. R., Sambrook P. N., Lanchbury J. S. Influence of vitamin D receptor genotype on bone mineral density in postmenopausal women: a twin study in Britain. BMJ. 1995 May 27;310(6991):1357–1360. doi: 10.1136/bmj.310.6991.1357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Storm T., Thamsborg G., Steiniche T., Genant H. K., Sørensen O. H. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med. 1990 May 3;322(18):1265–1271. doi: 10.1056/NEJM199005033221803. [DOI] [PubMed] [Google Scholar]
  19. Tilyard M. W., Spears G. F., Thomson J., Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med. 1992 Feb 6;326(6):357–362. doi: 10.1056/NEJM199202063260601. [DOI] [PubMed] [Google Scholar]
  20. Watts N. B., Harris S. T., Genant H. K., Wasnich R. D., Miller P. D., Jackson R. D., Licata A. A., Ross P., Woodson G. C., 3rd, Yanover M. J. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990 Jul 12;323(2):73–79. doi: 10.1056/NEJM199007123230201. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES